Certified by Founder Lodge
Frazier Life Sciences
United States - ND
INVESTOR
1 Disclosed Funding Rounds $85,000,000
5 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise o
| Company | Date | Round | Raised |
|---|---|---|---|
 Lassen Therapeutics |
December, 21 ,2023 | Series B | $85,000,000 |
 Sudo Biosciences |
December, 21 ,2023 | Series B | $116,000,000 |
 Radionetics Oncology |
January, 04 ,2024 | Series A | $52,500,000 |
 Bluejay Therapeutics |
May, 10 ,2024 | Series C | $182,000,000 |
 Attovia Therapeutics |
May, 14 ,2024 | Series B | $105,000,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
OTPLESS | $3,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
Aeropay | $20,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
